Search Results - "Rizvi, Hira A"

Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer by Schoenfeld, Adam J, Rizvi, Hira A, Memon, Danish, Shaverdian, Narek, Bott, Matthew J, Sauter, Jennifer L, Tsai, C Jillian, Lihm, Jayon, Hoyos, David, Plodkowski, Andrew J, Perez-Johnston, Rocio, Sawan, Peter, Egger, Jacklynn V, Greenbaum, Benjamin D, Rimner, Andreas, Riely, Gregory J, Rudin, Charles M, Rusch, Valerie W, Gomez, Daniel R, Hellmann, Matthew D

“…Clinical patterns and the associated optimal management of acquired resistance to PD-(L)1 blockade are poorly understood. All cases of metastatic lung cancer…”
Get full text

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection by Tio, Martin, Rai, Rajat, Ezeoke, Ogochukwu M., McQuade, Jennifer L., Zimmer, Lisa, Khoo, Chloe, Park, John J., Spain, Lavinia, Turajlic, Samra, Ardolino, Luke, Yip, Desmond, Goldinger, Simone M., Cohen, Justine V., Millward, Michael, Atkinson, Victoria, Kane, Alisa Y., Ascierto, Paolo A., Garbe, Claus, Gutzmer, Ralf, Johnson, Douglas B., Rizvi, Hira A., Joshua, Anthony M., Hellmann, Matthew D., Long, Georgina V., Menzies, Alexander M.

“…Anti-programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) immunotherapy is now routinely used to treat several cancers. Clinical trials have…”
Get full text

Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort by Arora, Kanika, Tran, Thinh N, Kemel, Yelena, Mehine, Miika, Liu, Ying L, Nandakumar, Subhiksha, Smith, Shaleigh A, Brannon, A Rose, Ostrovnaya, Irina, Stopsack, Konrad H, Razavi, Pedram, Safonov, Anton, Rizvi, Hira A, Hellmann, Matthew D, Vijai, Joseph, Reynolds, Thomas C, Fagin, James A, Carrot-Zhang, Jian, Offit, Kenneth, Solit, David B, Ladanyi, Marc, Schultz, Nikolaus, Zehir, Ahmet, Brown, Carol L, Stadler, Zsofia K, Chakravarty, Debyani, Bandlamudi, Chaitanya, Berger, Michael F

“…Accurate ancestry inference is critical for identifying genetic contributors of cancer disparities among populations. Although methods to infer genetic…”
Get more information

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers by Scharpf, Robert B, Balan, Archana, Ricciuti, Biagio, Fiksel, Jacob, Cherry, Christopher, Wang, Chenguang, Lenoue-Newton, Michele L, Rizvi, Hira A, White, James R, Baras, Alexander S, Anaya, Jordan, Landon, Blair V, Majcherska-Agrawal, Marta, Ghanem, Paola, Lee, Jocelyn, Raskin, Leon, Park, Andrew S, Tu, Huakang, Hsu, Hil, Arbour, Kathryn C, Awad, Mark M, Riely, Gregory J, Lovly, Christine M, Anagnostou, Valsamo

“…The RAS family of small GTPases represents the most commonly activated oncogenes in human cancers. To better understand the prevalence of somatic RAS mutations…”
Get full text